聚乙二醇洛塞那肽注射液 | China Drugs ListPolyethylene Glycol Loxenatide Injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 商品名
- 孚来美Fulaimei
- 企业
- 江苏豪森药业Jiangsu Hansoh Pharmaceutical
- 药品类型
- 生物药Biologic
- 治疗领域
- 内分泌与代谢Endocrinology & metabolism
- 公开来源记录的适应症
- 配合饮食控制和运动，单药或与二甲双胍联合，用于改善成人2型糖尿病患者的血糖控制。As an adjunct to diet and exercise, alone or in combination with metformin, to improve glycemic control in adults with type 2 diabetes.
- 适应症来源与口径
- 来源日期： 2025-09-19, 2026-10-23. 生产商面向中国大陆的药品说明书。 证据核查日期：2026年10月23日。Source date(s): 2025-09-19, 2026-10-23. Manufacturer prescribing information for Mainland China. Evidence review: 23 October 2026.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限二甲双胍等口服降糖药或胰岛素控制效果不佳的BMI≥25的患者，首次处方时需由二级及以上医疗机构专科医师开具处方。Limited to patients with BMI at least 25 whose glycemic control is inadequate with oral glucose-lowering drugs such as metformin or with insulin. The initial prescription must be issued by a specialist at a secondary-level or higher medical institution.
- 医保期限
- 2025-01-01 至 2026-12-312025-01-01 to 2026-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.